[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Pamela L. Kunz, Beth Chasen, Salvatore Tafuto, Secondo Lastoria, Jaume Capdevila, Amparo García-Burillo, Do‐Youn Oh, Changhoon Yoo, Thorvardur R Halfdanarson, Stephen A. Falk, Ilya Folitar, Yufen Zhang, Paola Aimone, Wouter W. de Herder, Diego Ferone